Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 7
Submit an article Journal homepage
376
Views
2
CrossRef citations to date
0
Altmetric
Letters to Editor

Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia

Fadi HaddadDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Hagop KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Ghayas C. IssaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Elias JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
&
Koji SasakiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9140-0610View further author information
ORCID Icon
Pages 1714-1717 | Received 13 Jan 2022, Accepted 13 Feb 2022, Published online: 01 Apr 2022

References

  • Kantarjian HM, Baccarani M, Jabbour E, et al. Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy. Clin Cancer Res. 2011;17(7):1674–1683.
  • Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–2340.
  • Khoury HJ, Gambacorti-Passerini C, Brümmendorf TH. Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia. Ann Oncol. 2018;29(3):578–587.
  • Molica M, Scalzulli E, Colafigli G, et al. Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia. Ther Adv Hematol. 2019;10:2040620719826444.
  • O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994–1004.
  • Quintás-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk. 2012;12(5):337–340.
  • Palmowski-Wolfe AM, Pape E, Baumann T, et al. Idiopathic intracranial hypertension: a possible association with imatinib. Eye Rep. 2011;1(1).
  • Chakupurakal G, Etti RJO, Murray JA. Peripheral neuropathy as an adverse effect of imatinib therapy. J Clin Pathol. 2011;64(5):456.
  • Kavanagh S, Bril V, Lipton JH. Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia. Blood Res. 2018;53(2):172–174.
  • Cortes JE, Jones D, O'Brien S, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol. 2010;28(3):398–404.
  • Ishida T, Akagawa N, Miyata T, et al. Dasatinib-associated reversible demyelinating peripheral polyneuropathy in a case of chronic myeloid leukemia. Int J Hematol. 2018;107(3):373–377.
  • Rafei H, Jabbour EJ, Kantarjian H, et al. Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series. Leuk Lymphoma. 2019;60(13):3292–3295.
  • Sotelo Monge K, Gálvez-Ruiz A, Alvárez-Carrón A, et al. Optic neuropathy secondary to dasatinib in the treatment of a chronic myeloid leukemia case. Saudi J Ophthalmol. 2015;29(3):227–231.
  • Ebnöether M, Stentoft J, Ford J, et al. Cerebral oedema as a possible complication of treatment with imatinib. Lancet. 2002;359(9319):1751–1752.
  • Mehtap O. A rare but fatal complication probably due to imatinib: cerebral edema. J Clin Case Rep. 2012;2(11).
  • Pavithran K, Thomas M. Idiopathic intracranial hypertension as the initial manifestation of chronic myeloid leukemia: letter to editor. Neurol India. 2002;50(2):230.
  • Sharma PV, Ilyas O, Jobanputra Y, et al. Is it always cancer? A curious case of benign intracranial hypertension in chronic myeloid leukemia. Intractable Rare Dis Res. 2018;7(3):182–184.
  • Guymer RH, Cairns JD, O'Day J. Benign intracranial hypertension in chronic myeloid leukemia. Aust N Z J Ophthalmol. 1993;21(3):181–185.
  • Bastin ME. Diffuse brain oedema in idiopathic intracranial hypertension: a quantitative magnetic resonance imaging study. J Neurol Neurosurg Psychiatry. 2003;74(12):1693–1696.
  • Wall M. Idiopathic intracranial hypertension. Arch Neurol. 1995;52(2):141.
  • Aduwa E, Szydlo R, Marin D, et al. Significant weight gain in patients with chronic myeloid leukemia after imatinib therapy. Blood. 2012;120(25):5087–5088.
  • Mestre H, Tithof J, Du T, et al. Flow of cerebrospinal fluid is driven by arterial pulsations and is reduced in hypertension. Nat Commun. 2018;9(1).
  • Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125(17):2128–2137.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.